Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population‐based cohort study in Sweden and Norway
Open Access
- 19 September 2019
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 103 (6) , 614-619
Abstract
Objective: To estimate survival in Swedish and Norwegian myelofibrosis (MF) patients who received ruxolitinib.Methods: Swedish and Norwegian patients with MF diagnosis in the National Cancer Registries (Sweden: 2001‐2015; Norway: 2002‐2016) and ≥1 record of ruxolitinib in the Prescribed Drug Registries (2013‐2017) were included. Patients were followed from ruxolitinib initiation until death or end of follow‐up; those who discontinued ruxolitinib were followed from ruxolitinib discontinuation. Relative survival (RS) and excess mortality rate ratios (EMRRs) were calculated vs a matched general population. Average loss in life expectancy (LEL) was predicted using flexible parametric models.Results: Among patients who initiated ruxolitinib (n = 190), 1‐ and 4‐year RS were 0.80 (95% confidence interval [CI]: 0.74, 0.86) and 0.52 (95% CI: 0.42, 0.64), respectively, and LEL was 11 years. EMRR was greater in patients aged >70 vs <60 years (3.16; 95% CI: 1.34‐7.40). Among patients who discontinued ruxolitinib (n = 71), median RS was 16.0 months (95% CI: 6.3, NE), and LEL was 12 years. After ruxolitinib treatment discontinuation, Swedish patients (n = 37) received glucocorticoids, hydroxyurea, busulfan, danazol and lenalidomide.Conclusion: Swedish and Norwegian MF patients who discontinued ruxolitinib had dismal survival outcomes and limited subsequent treatment options, highlighting the need for improved therapies.Keywords
Funding Information
- Janssen Research and Development
This publication has 17 references indexed in Scilit:
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analysesJournal of Hematology & Oncology, 2017
- Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuationBlood, 2017
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trialHaematologica, 2016
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisHaematologica, 2015
- Estimating the loss in expectation of life due to cancer using flexible parametric survival modelsStatistics in Medicine, 2013
- Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based StudyJournal of Clinical Oncology, 2012
- Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative NeoplasmsJournal of Clinical Oncology, 2011
- Data quality at the Cancer Registry of Norway: An overview of comparability, completeness, validity and timelinessEuropean Journal of Cancer, 2009
- The completeness of the Swedish Cancer Register – a sample survey for year 1998Acta Oncologica, 2009
- Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disordersLeukemia, 2008